<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069977</url>
  </required_header>
  <id_info>
    <org_study_id>031OTC1301</org_study_id>
    <nct_id>NCT02069977</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Aripiprazole</brief_title>
  <official_title>A Multinational, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Aripiprazole in Asian Pediatric Patients With Autism Spectrum Disorder and Behavior Problems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yoo-Sook Joung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka International Asia Arab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the efficacy of flexibly dosed aripiprazole in reducing serious behavioral&#xD;
           problems in Asian children and adolescents with a diagnosis of autism spectrum disorder,&#xD;
           as measured by change from baseline to endpoint on the irritability subscale of the&#xD;
           aberrant behavior checklist (ABC-I).&#xD;
&#xD;
        -  To evaluate the long-term safety and tolerability of flexibly dosed aripiprazole in the&#xD;
           treatment of serious behavioral problems in Asian children and adolescents with a&#xD;
           diagnosis of autism spectrum disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study design&#xD;
&#xD;
      - Multi-national, Multi-center, 52 weeks open label, single arm design&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>irritability subscale of the aberrant behavior checklist</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean change from baseline to endpoint of Part 1 (week 12)in the caregiver-rated ABC Irritability (ABC-I) subscale score.&#xD;
ABC Scale will be completed by subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech</measure>
    <time_frame>Week 1, 2, 4, 8, 12, 24, 36, 52</time_frame>
    <description>ABC Scale will be completed by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CGI-S, CGI-I from baseline</measure>
    <time_frame>Week 1, 2, 4, 8, 12, 24, 36, 52</time_frame>
    <description>CGI-S, CGI-I scale will be evaluated by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Behavioral problems from baseline</measure>
    <time_frame>Week 12, 52</time_frame>
    <description>Behavioral problems scale: Child Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Adaptive Skills from baseline</measure>
    <time_frame>week 12, 52</time_frame>
    <description>Adaptive Skills Scale: Vineland Adaptive Behavior Scale (VABS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Parental stress from baseline</measure>
    <time_frame>Weekk 12, 52</time_frame>
    <description>Parental stress scale: Parenting Stress Index (PSI)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Week 1, 2, 4, 8, 12, 24, 36, 52</time_frame>
    <description>Safety will be evaluated based on below inormaiton.&#xD;
Laboratory test results (routine lab. and serum prolactin)&#xD;
Vital signs (blood pressure, pulse, body temperature)&#xD;
ECG&#xD;
Weight gain&#xD;
Extrapyramidal side effects (EPSEs) assessed by Simpson-Angus Rating Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level: 2, 5, 10, 15 mg/day&#xD;
Starting dose: 2 mg/day&#xD;
Dose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.&#xD;
Target dose: 5-15 mg/day&#xD;
Maximum dose: 15 mg/day&#xD;
Flexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  6 to 17 years of age.&#xD;
&#xD;
          -  Meeting the diagnostic criteria for autistic disorder specified by the Diagnostic and&#xD;
             Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR),&#xD;
             with a diagnosis corroborated by the Autism Diagnostic Interview-Revised (ADI-R)&#xD;
             diagnostic instrument and demonstrated behaviors such as tantrums, aggression,&#xD;
             self-injurious behavior, or a combination of these.&#xD;
&#xD;
          -  Clinical Global Impressions (CGI) Severity subscale score ≥ 4 at screening and&#xD;
             baseline.&#xD;
&#xD;
          -  Aberrant Behavior Checklist (ABC) Irritability subscale score ≥18 at screening and&#xD;
             baseline.&#xD;
&#xD;
          -  Mental age ≥ 18 months.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) have to use an adequate method of&#xD;
             contraception&#xD;
&#xD;
          -  WOCBP must have had a negative serum or urine pregnancy test.&#xD;
&#xD;
          -  The patient and/or the designated guardian(s) or caregiver(s) who are able to&#xD;
             comprehend and comply with the protocol requirements, in the opinion of the&#xD;
             investigator and have consented to participate by signing an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of bipolar disorder, schizophrenia, major depressive disorder,&#xD;
             Rett's disorder, or Fragile-X syndrome.&#xD;
&#xD;
          -  History of neuroleptic malignant syndrome.&#xD;
&#xD;
          -  Significant risk of committing suicide based on history or routine psychiatric status&#xD;
             examination.&#xD;
&#xD;
          -  History of seizure in the past 1 year.&#xD;
&#xD;
          -  History of severe head trauma or stroke&#xD;
&#xD;
          -  History or current evidence of any unstable medical conditions&#xD;
&#xD;
          -  Patient considered treatment resistant to neuroleptic medication&#xD;
&#xD;
          -  Patient considered treatment resistant to aripiprazole&#xD;
&#xD;
          -  Woman who is pregnant or breastfeeding&#xD;
&#xD;
          -  ECG: QTc &gt; 475 msec&#xD;
&#xD;
          -  Platelets ≤ 75,000/μL&#xD;
&#xD;
          -  Hemoglobin ≤ 9 g/dL&#xD;
&#xD;
          -  Neutrophils ≤ 1.0x10^3/μL&#xD;
&#xD;
          -  Aspartate or alanine transaminase (AST or ALT) &gt; 3xULN&#xD;
&#xD;
          -  Serum creatinine ≥ 2 mg/dL&#xD;
&#xD;
          -  Patient weighed &lt; 15 kg&#xD;
&#xD;
          -  Patient who participated in any other clinical trial within 4 weeks&#xD;
&#xD;
          -  Patient determined to require the administration of the prohibited medications during&#xD;
             the study period&#xD;
&#xD;
          -  Patient with other conditions determined by the investigator to be inappropriate for&#xD;
             this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoo-Sook Joung, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sumsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyemi Cheon</last_name>
    <phone>82-70-4033-3059</phone>
    <email>cheon.hyemi@cnrres.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <state>Gyeonggi-do</state>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eun-Jin Park, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoo-Sook Joung, MD., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hyo-Won Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City</name>
      <address>
        <city>Pasig</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stella Manalo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Philippine Children's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexis Reyes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vitharon Boon-yasidhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>March 10, 2014</last_update_submitted>
  <last_update_submitted_qc>March 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Yoo-Sook Joung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Abilify</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

